Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model

R.J. Mairs; C.L. Wideman; W.J. Angerson; T.L. Whateley; M.S. Reza; J.R. Reeves; L.M. Robertson; A. Neshasteh-Riz

doi:10.1054/bjoc.1999.0879

Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model

R.J. Mairs, C.L. Wideman, W.J. Angerson, T.L. Whateley, M.S. Reza, J.R. Reeves, L.M. Robertson, A. Neshasteh-Riz

Research output: Contribution to journal › Article › peer-review

30 Citations (Scopus)

Abstract

As part of an NHS Executive Trent regional initiative we considered the role and cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. The key trials and case series show an additional patient benefit of 0.8-1.1 life years over standard chemotherapy. We estimate incremental cost per life year gained of £12 800-£17 600, which reduces further if long-term benefits are considered. High dose chemotherapy in these conditions is both life-saving and cost-effective.

Original language	English
Pages (from-to)	74-80
Number of pages	6
Journal	British Journal of Cancer
Volume	82
Issue number	1
DOIs	https://doi.org/10.1054/bjoc.1999.0879
Publication status	Published - Jan 2000

Keywords

radioiododeoxyuridine
glioma
intracerebral therapy
rat
sustained release
Hodgkin's disease
lymphoma
cost-effectiveness
high dose chemotherapy
transplantation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1054/bjoc.1999.0879

Cite this

@article{96f00369a35d4e89bac398b0c963ede5,

title = "Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model",

abstract = "As part of an NHS Executive Trent regional initiative we considered the role and cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. The key trials and case series show an additional patient benefit of 0.8-1.1 life years over standard chemotherapy. We estimate incremental cost per life year gained of £12 800-£17 600, which reduces further if long-term benefits are considered. High dose chemotherapy in these conditions is both life-saving and cost-effective.",

keywords = "radioiododeoxyuridine, glioma, intracerebral therapy, rat, sustained release, Hodgkin's disease, lymphoma, cost-effectiveness, high dose chemotherapy, transplantation",

author = "R.J. Mairs and C.L. Wideman and W.J. Angerson and T.L. Whateley and M.S. Reza and J.R. Reeves and L.M. Robertson and A. Neshasteh-Riz",

note = "Strathprints' policy is to record up to 8 authors per publication, plus any additional authors based at the University of Strathclyde. More authors may be listed on the official publication than appear in the Strathprints' record.",

year = "2000",

month = jan,

doi = "10.1054/bjoc.1999.0879",

language = "English",

volume = "82",

pages = "74--80",

journal = "British Journal of Cancer",

issn = "0007-0920",

number = "1",

}

TY - JOUR

T1 - Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model

AU - Mairs, R.J.

AU - Wideman, C.L.

AU - Angerson, W.J.

AU - Whateley, T.L.

AU - Reza, M.S.

AU - Reeves, J.R.

AU - Robertson, L.M.

AU - Neshasteh-Riz, A.

N1 - Strathprints' policy is to record up to 8 authors per publication, plus any additional authors based at the University of Strathclyde. More authors may be listed on the official publication than appear in the Strathprints' record.

PY - 2000/1

Y1 - 2000/1

N2 - As part of an NHS Executive Trent regional initiative we considered the role and cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. The key trials and case series show an additional patient benefit of 0.8-1.1 life years over standard chemotherapy. We estimate incremental cost per life year gained of £12 800-£17 600, which reduces further if long-term benefits are considered. High dose chemotherapy in these conditions is both life-saving and cost-effective.

AB - As part of an NHS Executive Trent regional initiative we considered the role and cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma. The key trials and case series show an additional patient benefit of 0.8-1.1 life years over standard chemotherapy. We estimate incremental cost per life year gained of £12 800-£17 600, which reduces further if long-term benefits are considered. High dose chemotherapy in these conditions is both life-saving and cost-effective.

KW - radioiododeoxyuridine

KW - glioma

KW - intracerebral therapy

KW - rat

KW - sustained release

KW - Hodgkin's disease

KW - lymphoma

KW - cost-effectiveness

KW - high dose chemotherapy

KW - transplantation

UR - http://dx.doi.org/10.1054/bjoc.1999.0879

U2 - 10.1054/bjoc.1999.0879

DO - 10.1054/bjoc.1999.0879

M3 - Article

SN - 0007-0920

VL - 82

SP - 74

EP - 80

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 1

ER -

Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this